Outsourcing inhalation product development

Until fairly recently, most large, fully integrated pharmaceutical and biotechnology companies liked to keep all aspects of product development and manufacturing in-house, under direct control of the company. Today, however, we estimate that the industry spends nearly one dollar out of every five on outsourced services, and Big Pharma has joined smaller companies in turning to contract development. In some areas of development and manufacturing, as much as two third of a company’s expenditures on an inhaled product may go towards outsourcing. And with the substantial growth of specialty, emerging, and virtual pharmaceutical and biotechnology companies, partnering for mission critical expertise and services has become the rule rather than an exception.